Tags

Type your tag names separated by a space and hit enter

Expanding the spectrum of neuromyelitis optica: friend or foe?
Curr Opin Ophthalmol 2007; 18(6):459-62CO

Abstract

PURPOSE OF REVIEW

Neuromyelitis optica is a severe inflammatory disease with selective involvement of the optic nerve and spinal cord and relative sparing of the brain. This paper will review the recent literature on neuromyelitis optica with special reference to the recently proposed changes in the diagnostic criteria and the broadening clinical spectrum of the disease.

RECENT FINDINGS

The revised proposed diagnostic criteria of neuromyelitis optica allow incorporation of the status of the recently discovered autoantibody, NMO-IgG, and the presence of brain abnormalities shown by magnetic resonance imaging. NMO-IgG has been found to have good sensitivity and specificity in distinguishing neuromyelitis optica from multiple sclerosis. About 60% of neuromyelitis optica patients can develop such brain abnormalities not typical of multiple sclerosis. The visual prognosis and ambulatory outcome of neuromyelitis optica is poor, and early, aggressive treatment may be warranted to prevent relapses resulting in severe disability.

SUMMARY

The clinical spectrum of neuromyelitis optica has expanded since the original description of the disease. Clinicians need to be aware of the recent developments in the diagnostic approach to neuromyelitis optica.

Authors+Show Affiliations

Neuro-ophthalmology Unit, Department of Ophthalmology, Ibn Sina Hospital, Kuwait City, Kuwait. r_behbehani@hotmail.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18162996

Citation

Behbehani, Raed. "Expanding the Spectrum of Neuromyelitis Optica: Friend or Foe?" Current Opinion in Ophthalmology, vol. 18, no. 6, 2007, pp. 459-62.
Behbehani R. Expanding the spectrum of neuromyelitis optica: friend or foe? Curr Opin Ophthalmol. 2007;18(6):459-62.
Behbehani, R. (2007). Expanding the spectrum of neuromyelitis optica: friend or foe? Current Opinion in Ophthalmology, 18(6), pp. 459-62.
Behbehani R. Expanding the Spectrum of Neuromyelitis Optica: Friend or Foe. Curr Opin Ophthalmol. 2007;18(6):459-62. PubMed PMID: 18162996.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expanding the spectrum of neuromyelitis optica: friend or foe? A1 - Behbehani,Raed, PY - 2007/12/29/pubmed PY - 2008/1/17/medline PY - 2007/12/29/entrez SP - 459 EP - 62 JF - Current opinion in ophthalmology JO - Curr Opin Ophthalmol VL - 18 IS - 6 N2 - PURPOSE OF REVIEW: Neuromyelitis optica is a severe inflammatory disease with selective involvement of the optic nerve and spinal cord and relative sparing of the brain. This paper will review the recent literature on neuromyelitis optica with special reference to the recently proposed changes in the diagnostic criteria and the broadening clinical spectrum of the disease. RECENT FINDINGS: The revised proposed diagnostic criteria of neuromyelitis optica allow incorporation of the status of the recently discovered autoantibody, NMO-IgG, and the presence of brain abnormalities shown by magnetic resonance imaging. NMO-IgG has been found to have good sensitivity and specificity in distinguishing neuromyelitis optica from multiple sclerosis. About 60% of neuromyelitis optica patients can develop such brain abnormalities not typical of multiple sclerosis. The visual prognosis and ambulatory outcome of neuromyelitis optica is poor, and early, aggressive treatment may be warranted to prevent relapses resulting in severe disability. SUMMARY: The clinical spectrum of neuromyelitis optica has expanded since the original description of the disease. Clinicians need to be aware of the recent developments in the diagnostic approach to neuromyelitis optica. SN - 1040-8738 UR - https://www.unboundmedicine.com/medline/citation/18162996/Expanding_the_spectrum_of_neuromyelitis_optica:_friend_or_foe L2 - http://Insights.ovid.com/pubmed?pmid=18162996 DB - PRIME DP - Unbound Medicine ER -